2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Profiling, Treatment Considerations, Biological Therapies, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Study Population, Human, Adult
PAPER

2108 Hyperbolic NAMPT inhibition creates a targetable proteasome dependency in chronic lymphocytic leukemia

Fang Hao, BS, Katie Williams2, Uxue Miranda Beitia3, Jazmin Urrutia4, Mehdi Gharghabi, PharmD5, Min Wu, PhD6, Michael Schelle, PhD7, Jennifer A. Woyach, MD8, Rosa Lapalombella, PhD9
1 Ohio State University, Columbus, United States
2 Ohio State University, Columbus, United States
3 Ohio State University, Columbus, United States
4 Ohio State University, Columbus, United States
5 Ohio State University, Columbus, United States
6 Remedy Plan Therapeutics, Gaithersburg, United States
7 Remedy Plan Therapeutics, Gaithersburg, United States
8 Ohio State University, Columbus, United States
9 Ohio State University, Columbus, United States
Background

Relapsed or refractory chronic lymphocytic leukemia (CLL) remains a major therapeutic challenge because of acquired genetic alterations and protective signals from the tumor microenvironment. Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD? salvage pathway, is upregulated in CLL and associated with inferior clinical outcomes. Although first-generation NAMPT inhibitors demonstrated promising preclinical activity, their clinical development has been limited by dose-dependent toxicities resulting from near-complete NAMPT inhibition. RPT1G is a first-in-class hyperbolic NAMPT inhibitor designed to preserve partial NAMPT activity while maintaining antitumor efficacy. However, the adaptive survival mechanisms induced by NAMPT inhibition remain poorly understood. We therefore hypothesized that NAMPT inhibition creates a targetable dependence on proteasome function that can be exploited by combining RPT1G with carfilzomib (CFZ).

Methods

A genome-wide CRISPR/Cas9 knockout screen was performed in MEC-1 cells treated with RPT1G. Combination activity between RPT1G and CFZ was evaluated in CLL cell lines and primary CLL samples using cell viability and Annexin V/propidium iodide assays. Similar studies were performed with bortezomib and ixazomib. Immunoblotting was used to assess ubiquitinated proteins and apoptotic signaling. Stable Noxa-knockdown cell lines were generated to evaluate the functional contribution of Noxa. Combination activity was further examined in HS-5 stromal and nurse-like cell (NLC) co-culture systems, TP53-deficient and BTK C481S-mutant CLL models, and primary venetoclax-relapsed CLL samples.

Results

Genome-wide CRISPR/Cas9 screening identified the ubiquitin–proteasome pathway among the significantly depleted pathways under RPT1G treatment (normalized enrichment score [NES], −3.92; adjusted P < 0.05), indicating that NAMPT inhibition increases CLL-cell dependence on proteasome function. Consistent with this finding, RPT1G synergized with CFZ across multiple CLL cell lines after 72 h (highest single-agent [HSA] synergy scores: HG-3, 32; MEC-1, 28; and OSU-CLL, 32; n = 3). Similar synergy was observed with the clinically approved proteasome inhibitors bortezomib and ixazomib.

In primary CLL samples, RPT1G plus CFZ significantly reduced cell viability compared with either agent alone at clinically achievable concentrations (CFZ, 1.25–6 nM; RPT1G, 10 μM). Viable cells were 20% following combination treatment, compared with 80% with CFZ and 90% with RPT1G alone (one-way ANOVA, P < 0.01; n = 9). Enhanced cytotoxicity was associated with accumulation of ubiquitinated proteins and increased PARP and caspase-3 cleavage.

Combination treatment increased Noxa protein abundance. Stable Noxa knockdown in HG-3 and MEC-1 cells significantly attenuated combination-induced apoptosis, resulting in a >30% increase in viable cells versus shRNA controls (P < 0.01). These findings support a functional role for Noxa in mediating the observed synergy.

Importantly, RPT1G plus CFZ retained activity in HS-5 stromal and NLC co-culture models despite microenvironment-mediated protection. Viable cells were 45% with the combination, compared with 95% with CFZ and 90% with RPT1G alone in NLC co-culture (P < 0.01; n = 6). The combination also remained highly active in TP53-deficient and BTK C481S-mutant CLL models and primary samples from patients with venetoclax-relapsed disease. In venetoclax-relapsed samples, viable cells were 25% with the combination, compared with 60% with CFZ and 90% with RPT1G alone (P < 0.01; n = 3). Together, these findings demonstrate activity across multiple clinically relevant mechanisms of therapeutic resistance.

Conclusions

NAMPT inhibition creates a targetable dependence on proteasome function in CLL. Pharmacologic co-targeting of NAMPT and the proteasome supports a novel therapeutic strategy that retains activity despite microenvironment-mediated protection and clinically relevant mechanisms of therapeutic resistance. These findings provide a strong preclinical rationale for clinical evaluation of RPT1G in combination with proteasome inhibitors for patients with relapsed or refractory CLL.

Fang Hao, BS: No relevant conflicts of interest to declare.